New drug with chemotherapy for advanced esophageal cancer
Part of Cancer clinical trials.
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of esophageal cancer called squamous cell carcinoma that is advanced or has spread.
- You must be able to take care of yourself and be up and about (ECOG score 0 or 1).
- You must be willing to provide a tissue sample from your tumor for testing.
- You must have completed any prior cancer treatment at least 4 weeks before starting, and any side effects should have improved.
- You cannot have certain other serious medical conditions, like active infections, lung disease, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug called adebrelimab before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for people with locally advanced disease.
This study tests a new experimental drug that combines two ways to boost your immune system to fight cancer. It is for people with advanced esophageal cancer whose cancer didn't respond to previous immunotherapy and chemotherapy.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.